Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with ...

Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment. The partnership will leverage OBT's OGAP-Verify discovery ...

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...

Oxford BioTherapeutics has partnered with Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.

Oxford BioTherapeutics inks multi-year collaboration with Roche to discover novel targets for antibody-based therapeutics to treat cancer: Oxford, UK Thursday, March 20, 2025, 17: ...

Oxford Biotherapeutics Ltd. is partnering with Roche AG to expand the current field of tumor antigens that can be drugged with antibodies, as part of a potential $1 billion-plus agreement. The ...